Endoxifen enteric-coated not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will continue treatment with their initial randomized medication for 3 weeks”In the company’s words, NCT06608641 on ClinicalTrials.gov
- Tested for
- Bipolar 1 Disorder
- Main trialPhase 3
- “Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus,…”In the company’s words, NCT06608641 on ClinicalTrials.gov
Other drugs for Bipolar 1 Disorder
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- NBI-1117568Neurocrine Biosciences · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Unknown | Jun 2025 | Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026